AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16449709
Drug: Benzodiazepine tapering-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine tapering-off programme without psychotherapy
Trial: 9419047
Drug: Placebo (from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (from ALS CNTF Treatment Study)
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (50 g) with Acarbose 100 mg
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (50 g) without Acarbose
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (75 g) with Acarbose 100 mg
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (75 g) without Acarbose
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (100 g) with Acarbose 100 mg
Trial: 3525270
Drug: Sucrose meal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose meal (100 g) without Acarbose
Trial: 3525270
Drug: Acarbose (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (0 mg, 50 mg, 100 mg, 200 mg) with fixed sucrose load (75 g)
Trial: 24613816
Drug: HFX (hyperfractionation),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX (hyperfractionation), 81.6 Gy/68 twice‐daily fractions/7 weeks
Trial: 24613816
Drug: SFX (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFX (standard fractionation), 70 Gy/35 daily fractions/7 weeks
Trial: 24613816
Drug: 7-week treatments
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-week treatments
Trial: 24151792
Drug: Training preschool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training preschool teachers using a manual covering health education, health promotion, incorporation of oral‐health‐friendly activities into the preschool curriculum, and hands‐on experience of oral examination.
Trial: 14597032
Drug: No IOP-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IOP-lowering treatment
Trial: 1442914
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection technique with plain lidocaine
Trial: 3956889
Drug: Radiotelemetry capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotelemetry capsule measurements
Trial: 3956889
Drug: Antisecretory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory agent
Trial: 30244873
Drug: PCV15 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV15 (both formulations)
Trial: 11071086
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (duration: 72-96 hours)
Trial: 31758589
Drug: Alkali-modified implants
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkali-modified implants
Trial: 31758589
Drug: Sandblasted implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted implants
Trial: 28399035
Drug: Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2b (1,000,000 units/cc) eye drops
Trial: 18594971
Drug: Amoxicillin, omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, omeprazole, furazolidone, bismuth (Group B)
Trial: 18594971
Drug: Amoxicillin, clarithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, clarithromycin, omeprazole (Group C)
Trial: 16439432
Drug: Acetazolamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (4 mg kg(‐1)) + Antioxidants (1 g ascorbic acid i.v. and 200 mg alpha‐tocopherol p.o.)
Trial: 16439432
Drug: Acetazolamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (4 mg kg(‐1)) + Placebo
Trial: 15238591
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg every 12 hours)
Trial: 12890401
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (adjusted doses)
Trial: 11208394
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment for 8 weeks, diet restriction, and regular exercise
Trial: 11208394
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 8 weeks, no behavioral treatment
Trial: 11208394
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment for 8 weeks followed by 42 months of intervention
Trial: 11208394
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 8 weeks followed by 42 months of non-intervention
Trial: 9235656
Drug: Local injections
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injections of glucocorticosteroids
Trial: 9235656
Drug: Glucocorticosteroids injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroids injections
Trial: 1389662
Drug: iohexol (intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (intraarterial injection)
Trial: 1389662
Drug: ioxaglate (intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate (intraarterial injection)
Trial: 1389662
Drug: ioxaglate (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate (intravenous injection)
Trial: 1389662
Drug: iohexol (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (intravenous injection)
Trial: 28482864
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (normal daily exercise routine)
Trial: 21415660
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg etoricoxib (nonsteroidal anti-inflammatory)
Trial: 21415660
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone (corticosteroid anti-inflammatory)
Trial: 18317068
Drug: Cetuximab 250
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 250 mg/m(2) weekly IV and gefitinib 250 mg/d PO
Trial: 12808176
Drug: Enoxaparin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (mean dose of 0.68 mg/kg)
Trial: 12808176
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (mean bolus of 42.1 IU/kg and continuous infusion of 57.8 IU/kg)
Trial: 8590960
Drug: G‐DAMME 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐DAMME 250 micrograms IV as a bolus at time 0'
Trial: 8590960
Drug: G‐DAMME preceded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐DAMME preceded by hGH
Trial: 1706666
Drug: low-dose epirubicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose epirubicin
Trial: 7042201
Drug: Unable to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unable to tolerate antacids
Trial: 7042201
Drug: Medication (antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (antacids or cimetidine)
Trial: 30834689
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation with di- and tripeptides
Trial: 30834689
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation based on hydrolyzed collagen
Trial: 30059671
Drug: GS-0976 20
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-0976 20 mg
Trial: 30059671
Drug: GS-0976 5
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-0976 5 mg
Trial: 11981362
Drug: Once-daily SQV-SGC/RTV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily SQV-SGC/RTV (1600/100 mg)
Trial: 2043500
Drug: DHAP (dexamethasone/high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHAP (dexamethasone/high‐dose cytarabine/cisplatin) for two courses at 3‐ to 4‐week intervals
Trial: 24418368
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy
Trial: 28697991
Drug: Carbamazepine 400
RxNorm normalized name: carbamazepine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 400 mg before surgery
Trial: 28697991
Drug: Addicted patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addicted patients (no treatment)
Trial: 10950231
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg oral insulin daily
Trial: 10950231
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg oral insulin daily
Trial: 9210279
Drug: Feminist-cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feminist-cognitive-behavioral treatment
Trial: 9210279
Drug: Process-psychodynamic treatment
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process-psychodynamic treatment
Trial: 1422321
Drug: 0.15 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/day of conjugated estrogens
Trial: 1422321
Drug: 0.30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/day of conjugated estrogens
Trial: 1422321
Drug: 0.15 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Trial: 1422321
Drug: 0.30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Trial: 2475690
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of verapamil
Trial: 31613320
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (HD) group took 4 mg 17ß‐estradiol/d orally.
Trial: 31613320
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (LD) group took 2 mg 17ß‐estradiol/d orally and placebo.
Trial: 20388497
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution (CHO)
Trial: 26034927
Drug: Alpha lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid (ALA) 600 mg/day
Trial: 24103510
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and copper syrup with zinc (10 mg of iron, 0.5 mg of copper, and 10 mg of zinc)
Trial: 24103510
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and copper syrup without zinc (10 mg of iron and 0.5 mg of copper)
Trial: 11128679
Drug: Probenecid and
RxNorm normalized name: Probenecid and Colchicine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid and aspirin 325 mg taken concomitantly
Trial: 11128679
Drug: Probenecid followed
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probenecid followed by aspirin 325 mg at 6 hours
Trial: 1478369
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (continuous subcutaneous insulin infusion)
Trial: 6487749
Drug: Ketoprofen capsules
RxNorm normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen capsules (200 mg)
Trial: 6487749
Drug: Sustained-release pellets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release pellets (200 mg)
Trial: 6487749
Drug: Sustained-release pellets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release pellets (200 mg) once every 24 h
Trial: 6487749
Drug: Ketoprofen capsules
RxNorm normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen capsules (50 mg) every 6 h
Trial: 30323322
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (5-day course)
Trial: 22748702
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg twice daily
Trial: 24593917
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (annual treatment)
Trial: 24593917
Drug: Annual treatment
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual treatment with oral azithromycin
Trial: 20699411
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 25 mg [(14)C]INCB018424
Trial: 20699411
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses of unlabeled INCB018424
Trial: 15773875
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulphate (40 mg daily)
Trial: 12114361
Drug: Clarithromycin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (400 mg/d for 7 days)
Trial: 12114361
Drug: Amoxicillin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1,500 mg/d for 7 days)
Trial: 12114361
Drug: Cefaclor (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (750 mg/d for 7 days)
Trial: 20180109
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (2 microg/kg)
Trial: 1459356
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GIP and GLP-1 [7-36 amide]
Trial: 22500712
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (1 bag/dose, two doses per day)
Trial: 12885685
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) with Primary Care Management (PCM)
Trial: 12885685
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) with Cognitive Behavior Therapy (CBT)
Trial: 10369493
Drug: Chitosan (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (four capsules twice daily for 28 days)
Trial: 10369493
Drug: Placebo (indistinguishable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (indistinguishable capsules, four capsules twice daily for 28 days)
Trial: 30207136
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg, followed by an infusion of 0.4 μg/kg/h
Trial: 23626461
Drug: Saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 2.5 mg
Trial: 23626461
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg
Trial: 21342412
Drug: Saxagliptin 10
RxNorm normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 10 mg
Trial: 15690976
Drug: Human neuronal
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human neuronal cells (hNT cells; LBS neurons) delivered in doses of 2 or 6 million cells in three or nine implants, or 5 or 10 million cells in 25 implants
Trial: 787957
Drug: Propranolol (80-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80-320 mg daily, with increments up to 1200 mg as needed)
Trial: 787957
Drug: Tranquilizers (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranquilizers (control group)
Trial: 31931026
Drug: Mock treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock treatment (control)
Trial: 28430638
Drug: TACE+C+L
RxNorm normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE+C+L
Trial: 26293519
Drug: Piperaquine-dihydroartemisinin administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperaquine-dihydroartemisinin administered after a high-fat, high-calorie meal
Trial: 26293519
Drug: Piperaquine-dihydroartemisinin administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperaquine-dihydroartemisinin administered after fasting
Trial: 28698335
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs
Trial: 28698335
Drug: Standard antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiepileptic drugs
Trial: 9525716
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with CCNU, vincristine, and prednisone
Trial: 9525716
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with eight-drugs-in-1-day regimen
Trial: 7787157
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg h.s.
Trial: 2568086
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg h.s.
Trial: 28142202
Drug: Deferasirox film-coated
RxNorm normalized name: deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox film-coated tablet (FCT)
Trial: 26092557
Drug: Docetaxel chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel chemotherapy plus androgen deprivation therapy (ADT)
Trial: 23533230
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) alone
Trial: 18972062
Drug: Cu-(II)-orotate-dihydrate (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cu-(II)-orotate-dihydrate (8 mg Cu daily)
Trial: 16550600
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and etoposide 120 mg/m2 days 1-3 for 6 cycles)
Trial: 16550600
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin and etoposide)
Trial: 12963761
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of acetaminophen, given six times daily
Trial: 7917773
Drug: lazabemide (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lazabemide (100-300 mg single dose and 100-350 mg twice daily for 7 days)
Trial: 2844876
Drug: Leukotriene E4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene E4 (lower dose)
Trial: 2844876
Drug: Leukotriene E4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene E4 (higher dose)
Trial: 18492534
Drug: Pravastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin therapy (20 to 40 mg)
Trial: 16567913
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of magnesium sulphate 250 mg/kg within half an hour of birth and subsequently 125 mg/kg at 24 and 48 hours of life
Trial: 7982415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no magnesium treatment)
Trial: 1286497
Drug: Flumazenil (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (mean dose: 0.73 mg)
Trial: 1286497
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean dose: 8.9 ml)
Trial: 28984909
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine
Trial: 30924578
Drug: fast-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fast-acting insulin aspart (faster aspart)
Trial: 26962719
Drug: Gabapentin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (maximum dose 1200 mg three times a day)
Trial: 10593710
Drug: Various fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various fixed-dose combination (FDC) formulations of rifampicin